Abstract
Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Androgen Antagonists / adverse effects
-
Animals
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / mortality
-
Bone Neoplasms / psychology
-
Bone Neoplasms / secondary*
-
Bone Resorption / drug therapy
-
Bone Resorption / etiology
-
Clinical Trials as Topic
-
Cost-Benefit Analysis
-
Diphosphonates / economics
-
Diphosphonates / pharmacology
-
Diphosphonates / therapeutic use*
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Humans
-
Male
-
Mice
-
Pain / etiology
-
Pain / prevention & control
-
Prostatic Neoplasms / pathology*
-
Quality of Life
-
Survival Analysis
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Diphosphonates